| Identification | Back Directory | [Name]
2-butylsulfinyl-4-phenyl-6-thiophen-2-ylthieno[5,4-b]pyridin-3-amine | [CAS]
459147-39-8 | [Synonyms]
CS-1608
SW033291
SW033291(SW-033291)
SW033291 >=98% (HPLC)
SW033291;SW-033291;SW033291;SW 033291
2-butylsulfinyl-4-phenyl-6-thiophen-2-ylthieno[5,4-b]pyridin-3-amine
2-(Butylsulfinyl)-4-phenyl-6-(2-thienyl)thieno[2,3-b]pyridin-3-amine
4-phenyl-6-(thiophen-2-yl)-2-thioxo-1,2-
dihydropyridine-3-carbonitrile
Thieno[2,3-b]pyridin-3-amine, 2-(butylsulfinyl)-4-phenyl-6-(2-thienyl)-
2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine
2-(Butane-1-sulfinyl)-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridin-3-ylamine
2-(Butane-1-sulfinyl)-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridin-3-ylamine (SW033291) | [Molecular Formula]
C21H20N2OS3 | [MDL Number]
MFCD02973087 | [MOL File]
459147-39-8.mol | [Molecular Weight]
412.59 |
| Chemical Properties | Back Directory | [Melting point ]
>99°C (Dec) | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
powder | [color ]
light yellow to yellow-green | [InChI]
1S/C21H20N2OS3/c1-2-3-12-27(24)21-19(22)18-15(14-8-5-4-6-9-14)13-16(23-20(18)26-21)17-10-7-11-25-17/h4-11,13H,2-3,12,22H2,1H3 | [InChIKey]
LCYAYKSMOVLVRL-UHFFFAOYSA-N | [SMILES]
NC1=C(S(CCCC)=O)SC2=NC(C3=CC=CS3)=CC(C4=CC=CC=C4)=C21 |
| Hazard Information | Back Directory | [Uses]
SW033291 is an inhibitor which maintains the ability to promote tissue regeneration through inhibition of prostaglandin-degrading enzyme 15-PGDH. | [Biological Activity]
SW033291 is an inhibitor of the prostaglandin-degrading enzyme 15-PGDH. PGE2 is known to promote hematopoiesis and to promote reeneration by causing stem cells to proliferate. 15-PGDH degrades prostaglandin PGE2 and is a negative regulator of tissue regeneration and repair. SW033291 inhibition of 15-PGDH doubled levels of PGE2 and doubled rates of colon and liver tissue regeneration. Mice given SW033291 after receiving a bone marrow transplant had a two- to threefold increase in the number of donor cells th at homed to the their bone marrow. | [in vivo]
SW033291 (10 mg/kg; intraperitoneal injection; twice daily; for 3 days; C57BL/6J mice) treatment for three consecutive days shows significant benefits, including a doubling of peripheral neutrophil counts, a 65% increase in marrow SKL cells, and a 71% increase in marrow SLAM cells[1]. | Animal Model: | C57BL/6J mice[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; twice daily; for 3 days ( for 5 doses) | | Result: | Showed significant benefits, including a doubling of peripheral neutrophil counts, a 65% increase in marrow SKL cells, and a 71% increase in marrow SLAM cells.
|
| [storage]
Store at -20°C |
|
|